Antidote to Factor Xa inhibitors moves a step closer

The makers of a novel antidote that reverses the anticoagulant effects of the factor Xa inhibitors announced that the second part of a phase 3 study testing the agent met its primary end pointThe antidote, an intravenous bolus of andexanet alfa (Portola Pharmaceuticals, San Francisco, CA), produced a "rapid reversal" of the anticoagulant effect of apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) in the ANNEXA-A study, according to the company.

To read more, click here